Gujarat Themis Biosyn Limited (BOM:506879)

Market Cap	33.38B
Revenue (ttm)	1.55B
Net Income (ttm)	526.59M
Shares Out	108.97M
EPS (ttm)	4.83
PE Ratio	63.48
Forward PE	n/a
Dividend	0.67 (0.22%)
Ex-Dividend Date	n/a

Volume	14,354
Average Volume	55,438
Open	315.90
Previous Close	315.45
Day's Range	303.10 - 316.00
52-Week Range	192.35 - 390.00
Beta	-0.16
RSI	60.56
Earnings Date	May 13, 2025

About Gujarat Themis Biosyn

Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis; Rifamycin-O; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India.

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1981
• Employees: 159
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 506879

Financial Performance

In 2023, Gujarat Themis Biosyn's revenue was 1.70 billion, an increase of 14.45% compared to the previous year's 1.48 billion. Earnings were 591.63 million, an increase of 2.06%.